Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application
Viral infections causing pandemics and chronic diseases are the main culprits implicated in devastating global clinical and socioeconomic impacts, as clearly manifested during the current COVID-19 pandemic. Immunoprophylaxis via mass immunisation with vaccines has been shown to be an efficient strat...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/13/12/2091 |
| _version_ | 1827670344624766976 |
|---|---|
| author | Ana Sara Cordeiro Yogita Patil-Sen Maitreyi Shivkumar Ronak Patel Abdulwahhab Khedr Mohamed A. Elsawy |
| author_facet | Ana Sara Cordeiro Yogita Patil-Sen Maitreyi Shivkumar Ronak Patel Abdulwahhab Khedr Mohamed A. Elsawy |
| author_sort | Ana Sara Cordeiro |
| collection | DOAJ |
| description | Viral infections causing pandemics and chronic diseases are the main culprits implicated in devastating global clinical and socioeconomic impacts, as clearly manifested during the current COVID-19 pandemic. Immunoprophylaxis via mass immunisation with vaccines has been shown to be an efficient strategy to control such viral infections, with the successful and recently accelerated development of different types of vaccines, thanks to the advanced biotechnological techniques involved in the upstream and downstream processing of these products. However, there is still much work to be done for the improvement of efficacy and safety when it comes to the choice of delivery systems, formulations, dosage form and route of administration, which are not only crucial for immunisation effectiveness, but also for vaccine stability, dose frequency, patient convenience and logistics for mass immunisation. In this review, we discuss the main vaccine delivery systems and associated challenges, as well as the recent success in developing nanomaterials-based and advanced delivery systems to tackle these challenges. Manufacturing and regulatory requirements for the development of these systems for successful clinical and marketing authorisation were also considered. Here, we comprehensively review nanovaccines from development to clinical application, which will be relevant to vaccine developers, regulators, and clinicians. |
| first_indexed | 2024-03-10T03:19:45Z |
| format | Article |
| id | doaj.art-be50fd8b2efd4d7397d07dcf282a5855 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T03:19:45Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-be50fd8b2efd4d7397d07dcf282a58552023-11-23T10:05:47ZengMDPI AGPharmaceutics1999-49232021-12-011312209110.3390/pharmaceutics13122091Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical ApplicationAna Sara Cordeiro0Yogita Patil-Sen1Maitreyi Shivkumar2Ronak Patel3Abdulwahhab Khedr4Mohamed A. Elsawy5Leicester Institute for Pharmaceutical Innovation, Leicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, UKWrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, National Health Service, Wigan WN6 0SZ, UKLeicester Institute for Pharmaceutical Innovation, Leicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, UKSchool of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UKLeicester Institute for Pharmaceutical Innovation, Leicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, UKLeicester Institute for Pharmaceutical Innovation, Leicester School of Pharmacy, De Montfort University, Leicester LE1 9BH, UKViral infections causing pandemics and chronic diseases are the main culprits implicated in devastating global clinical and socioeconomic impacts, as clearly manifested during the current COVID-19 pandemic. Immunoprophylaxis via mass immunisation with vaccines has been shown to be an efficient strategy to control such viral infections, with the successful and recently accelerated development of different types of vaccines, thanks to the advanced biotechnological techniques involved in the upstream and downstream processing of these products. However, there is still much work to be done for the improvement of efficacy and safety when it comes to the choice of delivery systems, formulations, dosage form and route of administration, which are not only crucial for immunisation effectiveness, but also for vaccine stability, dose frequency, patient convenience and logistics for mass immunisation. In this review, we discuss the main vaccine delivery systems and associated challenges, as well as the recent success in developing nanomaterials-based and advanced delivery systems to tackle these challenges. Manufacturing and regulatory requirements for the development of these systems for successful clinical and marketing authorisation were also considered. Here, we comprehensively review nanovaccines from development to clinical application, which will be relevant to vaccine developers, regulators, and clinicians.https://www.mdpi.com/1999-4923/13/12/2091vaccinevirusnanomaterialsdeliveryimmunisation |
| spellingShingle | Ana Sara Cordeiro Yogita Patil-Sen Maitreyi Shivkumar Ronak Patel Abdulwahhab Khedr Mohamed A. Elsawy Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application Pharmaceutics vaccine virus nanomaterials delivery immunisation |
| title | Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application |
| title_full | Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application |
| title_fullStr | Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application |
| title_full_unstemmed | Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application |
| title_short | Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application |
| title_sort | nanovaccine delivery approaches and advanced delivery systems for the prevention of viral infections from development to clinical application |
| topic | vaccine virus nanomaterials delivery immunisation |
| url | https://www.mdpi.com/1999-4923/13/12/2091 |
| work_keys_str_mv | AT anasaracordeiro nanovaccinedeliveryapproachesandadvanceddeliverysystemsforthepreventionofviralinfectionsfromdevelopmenttoclinicalapplication AT yogitapatilsen nanovaccinedeliveryapproachesandadvanceddeliverysystemsforthepreventionofviralinfectionsfromdevelopmenttoclinicalapplication AT maitreyishivkumar nanovaccinedeliveryapproachesandadvanceddeliverysystemsforthepreventionofviralinfectionsfromdevelopmenttoclinicalapplication AT ronakpatel nanovaccinedeliveryapproachesandadvanceddeliverysystemsforthepreventionofviralinfectionsfromdevelopmenttoclinicalapplication AT abdulwahhabkhedr nanovaccinedeliveryapproachesandadvanceddeliverysystemsforthepreventionofviralinfectionsfromdevelopmenttoclinicalapplication AT mohamedaelsawy nanovaccinedeliveryapproachesandadvanceddeliverysystemsforthepreventionofviralinfectionsfromdevelopmenttoclinicalapplication |